Calcineurin protects the heart in a murine model of dilated cardiomyopathy

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 6, 2010, Pages 1080-1087

  Heineke, Joerg ^a,b   Wollert, Kai C ^b   Osinska, Hanna ^a   Sargent, Michelle A ^a   York, Allen J ^a   Robbins, Jeffrey ^a   Molkentin, Jeffery D ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Apoptosis; Calcineurin; Dilated Cardiomyopathy; Muscle Lim Protein; Necrosis

Indexed keywords

CALCINEURIN; ISOPROTEIN; LIM PROTEIN; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL ULTRASTRUCTURE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; KNOCKOUT MOUSE; MOLECULAR MECHANICS; MORTALITY; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN TARGETING; RISK REDUCTION;

ANIMALS; CALCINEURIN; CALCIUM; CARDIOMYOPATHY, DILATED; CELL DEATH; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; GENE EXPRESSION REGULATION; HEART; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MYOCARDIUM;

MURINAE; MUS;

EID: 77952674605     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.10.012     Document Type: Article

References (35)

1. Towbin J.A., Lowe A.M., Colan S.D., Sleeper L.A., Orav E.J., Clunie S., et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006 Oct 18, 296(15):1867-1876.
2. Grunig E., Tasman J.A., Kucherer H., Franz W., Kubler W., Katus H.A. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol 1998 Jan, 31(1):186-194.
3. Arber S., Halder G., Caroni P. Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation. Cell 1994 Oct 21, 79(2):221-231.
4. Arber S., Hunter J.J., Ross J., Hongo M., Sansig G., Borg J., et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997 Feb 7, 88(3):393-403.
5. Knoll R., Hoshijima M., Hoffman H.M., Person V., Lorenzen-Schmidt I., Bang M.L., et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 2002 Dec 27, 111(7):943-955.
6. Recchia F.A., Lionetti V. Animal models of dilated cardiomyopathy for translational research. Vet Res Commun 2007 Aug, 31(Suppl 1):35-41.
7. Zolk O., Caroni P., Bohm M. Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. Circulation 2000 Jun 13, 101(23):2674-2677.
8. Heineke J., Kempf T., Kraft T., Hilfiker A., Morawietz H., Scheubel R.J., et al. Downregulation of cytoskeletal muscle LIM protein by nitric oxide: impact on cardiac myocyte hypertrophy. Circulation 2003 Mar 18, 107(10):1424-1432.
9. Heineke J., Ruetten H., Willenbockel C., Gross S.C., Naguib M., Schaefer A., et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci U S A 2005 Feb 1, 102(5):1655-1660.
10. Bueno O.F., van Rooij E., Molkentin J.D., Doevendans P.A., De Windt L.J. Calcineurin and hypertrophic heart disease: novel insights and remaining questions. Cardiovasc Res 2002 Mar, 53(4):806-821.
11. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006 Aug, 7(8):589-600.
12. Bueno O.F., Wilkins B.J., Tymitz K.M., Glascock B.J., Kimball T.F., Lorenz J.N., et al. Impaired cardiac hypertrophic response in calcineurin Abeta-deficient mice. Proc Natl Acad Sci U S A 2002 Apr 2, 99(7):4586-4591.
13. Taigen T., De Windt L.J., Lim H.W., Molkentin J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A 2000 Feb 1, 97(3):1196-1201.
14. Lim H.W., Molkentin J.D. Calcineurin and human heart failure. Nat Med 1999 Mar, 5(3):246-247.
15. Haq S., Choukroun G., Lim H., Tymitz K.M., del Monte F., Gwathmey J., et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001 Feb 6, 103(5):670-677.
16. Sussman M.A., Lim H.W., Gude N., Taigen T., Olson E.N., Robbins J., et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998 Sep 11, 281(5383):1690-1693.
17. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998 Apr 17, 93(2):215-228.
18. Wilkins B.J., Dai Y.S., Bueno O.F., Parsons S.A., Xu J., Plank D.M., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004 Jan 9, 94(1):110-118.
19. Sanbe A., Gulick J., Hanks M.C., Liang Q., Osinska H., Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 2003 Apr 4, 92(6):609-616.
20. Parsons S.A., Millay D.P., Sargent M.A., McNally E.M., Molkentin J.D. Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 2006 Jun, 168(6):1975-1985.
21. Fewell J.G., Osinska H., Klevitsky R., Ng W., Sfyris G., Bahrehmand F., et al. A treadmill exercise regimen for identifying cardiovascular phenotypes in transgenic mice. Am J Physiol 1997 Sep, 273(3 Pt 2):H1595-H1605.
22. Gold R., Schmied M., Giegerich G., Breitschopf H., Hartung H.P., Toyka K.V., et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 1994 Aug, 71(2):219-225.
23. Al-Lamki R.S., Skepper J.N., Loke Y.W., King A., Burton G.J. Apoptosis in the early human placental bed and its discrimination from necrosis using the in-situ DNA ligation technique. Hum Reprod 1998 Dec, 13(12):3511-3519.
24. Guerra S., Leri A., Wang X., Finato N., Di Loreto C., Beltrami C.A., et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999 Oct 29, 85(9):856-866.
25. Fujio Y., Nguyen T., Wencker D., Kitsis R.N., Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000 Feb 15, 101(6):660-667.
26. Purcell N.H., Wilkins B.J., York A., Saba-El-Leil M.K., Meloche S., Robbins J., et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A 2007 Aug 28, 104(35):14074-14079.
27. Shiraishi I., Melendez J., Ahn Y., Skavdahl M., Murphy E., Welch S., et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ Res 2004 Apr 16, 94(7):884-891.
28. Kostin S., Pool L., Elsasser A., Hein S., Drexler H.C., Arnon E., et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003 Apr 18, 92(7):715-724.
29. Foo R.S., Mani K., Kitsis R.N. Death begets failure in the heart. J Clin Invest 2005 Mar, 115(3):565-571.
30. Wencker D., Chandra M., Nguyen K., Miao W., Garantziotis S., Factor S.M., et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003 May, 111(10):1497-1504.
31. Nakayama H., Chen X., Baines C.P., Klevitsky R., Zhang X., Zhang H., et al. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007 Sep, 117(9):2431-2444.
32. Hirota H., Chen J., Betz U.A., Rajewsky K., Gu Y., Ross J., et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999 Apr 16, 97(2):189-198.
33. Bueno O.F., Lips D.J., Kaiser R.A., Wilkins B.J., Dai Y.S., Glascock B.J., et al. Calcineurin Abeta gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction. Circ Res 2004 Jan 9, 94(1):91-99.
34. De Windt L.J., Lim H.W., Taigen T., Wencker D., Condorelli G., Dorn G.W., et al. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: an apoptosis-independent model of dilated heart failure. Circ Res 2000 Feb 18, 86(3):255-263.
35. Pu W.T., Ma Q., Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res 2003 Apr 18, 92(7):725-731.